Body fluid regulation via chronic inhibition of sodium–glucose cotransporter-2 in patients with heart failure: a post hoc analysis of the CANDLE trial

被引：0
|
作者：
Shinya Fujiki
Atsushi Tanaka
Takumi Imai
Michio Shimabukuro
Hiroki Uehara
Ikuko Nakamura
Kazuo Matsunaga
Makoto Suzuki
Takeshi Kashimura
Tohru Minamino
Takayuki Inomata
Koichi Node
机构：
[1] Niigata University Graduate School of Medical and Dental Sciences,Department of Cardiovascular Medicine
[2] Saga University,Department of Cardiovascular Medicine
[3] Osaka City University Graduate School of Medicine,Department of Medical Statistics
[4] Fukushima Medical University,Department of Diabetes, Endocrinology, and Metabolism
[5] Urasoe General Hospital,Division of Cardiology
[6] Saga-Ken Medical Centre Koseikan,Department of Cardiovascular Medicine
[7] Imari-Arita Kyoritsu Hospital,Department of Internal Medicine
[8] Yokohama Minami Kyosai Hospital,Department of Cardiology
[9] Juntendo University Graduate School of Medicine,Department of Cardiovascular Biology and Medicine
来源：
Clinical Research in Cardiology | 2023年 / 112卷
关键词：
Sodium–glucose cotransporter-2 (SGLT2) inhibitor; Canagliflozin; Estimated plasma volume (ePV); Estimated extracellular volume (eEV); Estimated glomerular filtration rate (eGFR); HFpEF; HFrEF;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：87 / 97
页数：10
相关论文
共 50 条
  • [41] Sodium-glucose cotransporter-2 inhibitors improve liver enzymes in patients with co-existing non-alcoholic fatty liver disease: a systematic review and meta-analysis
    Amjad, Waseem
    Malik, Adnan
    Qureshi, Waqas
    Dennis, Brittany
    Mumtaz, Mirrah
    Haider, Rabbia
    Jamal, Shakeel
    Jaura, Faisal
    Ahmed, Aijaz
    GASTROENTEROLOGY REVIEW-PRZEGLAD GASTROENTEROLOGICZNY, 2022, 17 (04): : 288 - 300
  • [42] The sodium-glucose cotransporter-2 inhibitor canagliflozin does not increase risk of non-genital skin and soft tissue infections in people with type 2 diabetes mellitus: A pooled post hoc analysis from the CANVAS Program and CREDENCE randomized double-blind trials
    Kang, Amy
    Smyth, Brendan
    Neuen, Brendon L. L.
    Heerspink, Hiddo J. L.
    Di Tanna, Gian Luca
    Zhang, Hong
    Arnott, Clare
    Hockham, Carinna
    Agarwal, Rajiv
    Bakris, George
    Charytan, David M. M.
    de Zeeuw, Dick
    Greene, Tom
    Levin, Adeera
    Pollock, Carol
    Wheeler, David C. C.
    Mahaffey, Kenneth W. W.
    Perkovic, Vlado
    Jardine, Meg J. J.
    DIABETES OBESITY & METABOLISM, 2023, 25 (08) : 2151 - 2162
  • [43] Sodium-glucose cotransporter-2 inhibitors improve clinical outcomes in patients with type 2 diabetes mellitus undergoing anthracycline-containing chemotherapy: an emulated target trial using nationwide cohort data in South Korea
    Hwang, Hui-Jeong
    Kim, Minji
    Jun, Ji Eun
    Yon, Dong Keon
    SCIENTIFIC REPORTS, 2023, 13 (01):
  • [44] Efficacy and safety of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors as monotherapy or add-on to metformin in patients with type 2 diabetes mellitus: A systematic review and meta-analysis
    Wang, Zhiying
    Sun, Jiahui
    Han, Ruobing
    Fan, Dongzhu
    Dong, Xinyi
    Luan, Zenghui
    Xiang, Rongwu
    Zhao, Mingyi
    Yang, Jingyu
    DIABETES OBESITY & METABOLISM, 2018, 20 (01) : 113 - 120
  • [45] Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis
    Michael Pfeifer
    Raymond R. Townsend
    Michael J. Davies
    Ujjwala Vijapurkar
    Jimmy Ren
    Cardiovascular Diabetology, 16
  • [46] Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis
    Pfeifer, Michael
    Townsend, Raymond R.
    Davies, Michael J.
    Vijapurkar, Ujjwala
    Ren, Jimmy
    CARDIOVASCULAR DIABETOLOGY, 2017, 16
  • [47] The effect of sodium-glucose cotransporter 2 inhibitors in patients with chronic kidney disease with or without type 2 diabetes mellitus on cardiovascular and renal outcomes: A systematic review and meta-analysis
    Reyes-Farias, Carlos Ignacio
    Reategui-Diaz, Marcelo
    Romani-Romani, Franco
    Prokop, Larry
    PLOS ONE, 2023, 18 (11):
  • [48] Cardiovascular Safety, Long-Term Noncardiovascular Safety, and Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Systemic Review and Meta-Analysis With Trial Sequential Analysis
    Zhang, Xin-Lin
    Zhu, Qing-Qing
    Chen, Yu-Han
    Li, Xue-Ling
    Chen, Fu
    Huang, Jian-An
    Xu, Biao
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2018, 7 (02):
  • [49] Influence of left ventricular ejection fraction on the reduction in N-terminal pro-brain natriuretic peptide by canagliflozin in patients with heart failure and type 2 diabetes: A sub analysis of the CANDLE trial
    Ohte, Nobuyuki
    Tanaka, Atsushi
    Kitada, Shuichi
    Yamada, Takahisa
    Eguchi, Kazuo
    Teragawa, Hiroki
    Takeishi, Yasuchika
    Kodama, Kazuhisa
    Seo, Yoshihiro
    Node, Koichi
    JOURNAL OF CARDIOLOGY, 2023, 81 (06) : 508 - 512
  • [50] Effect of Canagliflozin Compared With Sitagliptin on Serum Lipids in Patients with Type 2 Diabetes Mellitus and Heart Failure with Reduced Ejection Fraction: A Post-Hoc Analysis of the CANA-HF Study
    Dixon, Dave L.
    Billingsley, Hayley E.
    Canada, Justin M.
    Trankle, Cory R.
    Kadariya, Dinesh
    Cooke, Richard
    Hart, Linda
    Van Tassell, Benjamin
    Abbate, Antonio
    Carbone, Salvatore
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2021, 78 (03) : 407 - 410
12345